Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Table 4 Multivariate Cox regression analysis of progression-free survival

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age (≤ 58 vs > 58 yr)	0.98 (0.64-1.49)	0.9279
Gender (male vs female)	0.64 (0.31-1.32)	0.1413
ECOG PS (0 vs 1)	0.90 (0.59-1.37)	0.6087
Etiology (HBV vs others)	0.78 (0.45-1.36)	0.3417
BCLC stage (C vs B)	1.82 (1.18-2.80)	0.0036	1.75 (1.12-2.74)	0.014
Maximum tumor diameter (≤ 6.8 vs > 6.8)	0.99 (0.65-1.52)	0.9933
Number of tumors (≤ 3 vs > 3)	0.81 (0.53-1.23)	0.3099
Portal vein invasion (absent vs presence)	0.77 (0.47-1.26)	0.2597
Extrahepatic metastasis (absent vs presence)	0.73 (0.47-1.14)	0.1408
Child-Pugh class (A vs B)	1.26 (0.67-2.36)	0.5094
Baseline AFP (≤ 400 vs > 400)	1.00 (0.65-1.53)	0.9992
Baseline DCP (≤ 40 vs > 40)	1.27 (0.64-2.55)	0.4486
NLR (≤ 3 vs > 3)	0.93 (0.56-1.54)	0.7707
LDH (≤ 198.52 vs > 198.52)	0.85 (0.53-1.35)	0.4605
Early NLR response (decrease vs increase)	0.54 (0.34-0.86)	0.0025	0.56 (0.35-0.90)	0.016
Early AFP response (decrease ≤ 20% vs > 20%)	1.70 (1.08-2.66)	0.0116	1.73 (1.12-2.66)	0.013
Early DCP response (decrease ≤ 20% vs > 20%)	1.73 (0.97-3.09)	0.0250

AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer Classification; DCP: Des-gamma-carboxyprothrombin; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HBV: Hepatitis B virus; HR: Hazard ratio; LDH: Lactate dehydrogenase; NLR: Neutrophil lymphocyte ratio; PD-1: Programmed cell death protein-1.